Accuray Q4 revenue falls as tariff concerns, geopolitical tensions weigh on demand
ARAY•Drivers behind the quarterly results
- Product revenue decline - Co said lower product sales drove the 21% yr/yr revenue decrease in Q4, with demand in some regions affected by geopolitical developments and tariff uncertainty
- Service revenue growth - Q4 service revenue rose 6% yr/yr, which co said reflects continued momentum in its recurring revenue business
- Cost and margin improvement - Co said its transformation plan delivered over $20 mln in cost and margin improvements in fiscal 2026, exceeding its original target
Key financial details and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q4 Revenue | Miss | $100.92 mln | $105.30 mln (1 Analyst) |
| Q4 Loss Per Share | $0.02 | ||
| Q4 Net Loss | $1.94 mln | ||
| Q4 Gross Profit | $35.08 mln | ||
| Q4 Income From Operations | $5.52 mln | ||
| Q4 Loss Per Basic Share | $0.02 | ||
| Q4 Operating Expenses | $29.55 mln |
- The one available analyst rating on the shares is "hold"
- The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
- Wall Street's median 12-month price target for Accuray Incorporated is $0.35, about 11.1% above its August 18 closing price of $0.32
